TOP TEN perturbations for 38963_i_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38963_i_at
Selected probe(set): 38964_r_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38963_i_at (38964_r_at) across 6674 perturbations tested by GENEVESTIGATOR:
cutaneous sarcoidosis study 1 (lesional) / cutaneous sarcoidosis study 1 (non-lesional)
Relative Expression (log2-ratio):2.021696Number of Samples:13 / 9
Experimental | cutaneous sarcoidosis study 1 (lesional) |
Lesional skin biopsies from patients with acute cutaneous sarcoidosis. | |
Control | cutaneous sarcoidosis study 1 (non-lesional) |
Non-lesional skin biopsies from patients with acute cutaneous sarcoidosis. |
cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue
Relative Expression (log2-ratio):1.913187Number of Samples:4 / 8
Experimental | cutaneous T-cell lymphoma study 1 (tumor phase) |
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal). | |
Control | normal skin tissue |
Skin biopsies from healthy individuals. |
cutaneous sarcoidosis study 1 (lesional) / normal skin tissue
Relative Expression (log2-ratio):1.9012613Number of Samples:13 / 5
Experimental | cutaneous sarcoidosis study 1 (lesional) |
Lesional skin biopsies from patients with acute cutaneous sarcoidosis. | |
Control | normal skin tissue |
Skin biopsy samples from healthy control subjects. |
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-1.7649984Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal skin tissue |
Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
adrenal gland cancer study 4 / normal adrenal cortex tissue
Relative Expression (log2-ratio):-1.6463223Number of Samples:43 / 4
Experimental | adrenal gland cancer study 4 |
Primary tumor tissue samples of the adrenal cortex from patients with adrenocortical carcinoma (ACC). | |
Control | normal adrenal cortex tissue |
Histological normal adrenal gland cortical tissue samples derived after autopsy. |
glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):1.4777966Number of Samples:2 / 4
Experimental | glioma study 17 (glioblastoma; unsorted) |
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. | |
Control | non-tumor cortical tissue |
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
small cell lung cancer study 4 (XCL from CDX) / small cell lung cancer study 4 (cell line)
Relative Expression (log2-ratio):-1.4594402Number of Samples:11 / 4
Experimental | small cell lung cancer study 4 (XCL from CDX) |
Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) publicly available cell lines derived xenografts (CDX derived cell lines). Xenografts were grown in the flanks of a nude mice. Obtained cells were cultivated under conventional tissue culture conditions. | |
Control | small cell lung cancer study 4 (cell line) |
Various small cell lung cancer (SCLC) publicly available cell lines samples. |
diphenylcyclopropenone study 1 (early) / placebo treated skin tissue
Relative Expression (log2-ratio):1.4233952Number of Samples:10 / 11
Experimental | diphenylcyclopropenone study 1 (early) |
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:--- | |
Control | placebo treated skin tissue |
Skin biopsy samples of healthy volunteers exposed to placebo for 3 days. |
E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample
Relative Expression (log2-ratio):-1.4151735Number of Samples:5 / 7
Experimental | E. coli study 2 |
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli. | |
Control | unstimulated, normal monocyte-derived macrophage sample |
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated. |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):-1.4042683Number of Samples:3 / 4
Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |